HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the Australian Patent Office (Patent Number 2017207445) covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells.
Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine. Cartilage tissue, due to a lack of vascularization, has a limited capacity to heal when damaged, potentially leading to pain, inflammation, and loss of function in the affected joint. FibroBiologics’ fibroblast cell-based technology offers a potential solution to regenerate cartilage tissue and restore its function, by using a natural and biocompatible cellular blend that can adapt to the specific needs of the target tissue.
“The awarding of this patent recognizes the novelty and utility of our method for cartilage regeneration using fibroblast and other cell types. It strengthens our position in fibroblast cell therapy and regenerative medicine,” said Founder & Chief Executive Officer of FibroBiologics, Pete O’Heeron.
“Discs are complex structures that act as shock absorbers between the bones and require a delicate balance of mechanical, biochemical, and cellular factors to maintain health and function. Disc degeneration is a multifactorial process that involves the loss of proteoglycans and chondrocytes from the nucleus pulposus. Our fibroblast cell-based technology has the potential to replenish the nucleus pulposus with its essential secreted components, facilitating cell differentiation and modulating the inflammatory and degenerative environment of the disc. We believe that the methodology described in our issued patent has the potential to offer a long-lasting and minimally invasive solution for disc repair and regeneration,” added Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D.
For more information, please visit FibroBiologics’ website or email FibroBiologics at: [email protected].
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts and fibroblast cell-based technology to regenerate cartilage tissue, restore its function, and offer a long-lasting and minimally invasive solution for disc repair and regeneration, modulate the inflammatory and degenerative environment of the disc, and offer clinical benefits for patients. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to maintain and defend its intellectual property. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
[email protected]
Investor Relations:
Nic Johnson or Harrison Seidner, Ph.D.
Russo Partners
212-845-4242
[email protected]
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]
Bay Street News
